近5年，我们设计、构建了多种显著提高肿瘤化疗药物疗效及降低其毒副作用的新型药物纳米递释系统，并初步揭示了其作用机理，发表SCI论文247篇(其中IF>10论文29篇)，包括Adv Mater、Adv Drug Deliv Rev、Angew Chem Int Ed、ACS Nano、JACS和Adv Funct Mater等国际著名刊物，论文累计他引5326次，单篇最高他引208次；申请发明专利18项（授权10项）; 获新药证书1本，临床批件2项，特别是研究开发了国内外第一个以提高耐药肿瘤疗效为目标的纳米制剂新药；应邀在国内外学术大会上作大会或特邀报告60余次；获上海药学科技一等奖2项等。形成了以发展抗癌药物递释系统新理论、新技术和新方法，提高抗癌药物疗效并向临床应用转化为目标的多学科交叉、紧密结合的创新研究群体，在国内外药物递释系统领域产生了引领和示范作用。

In recent 5 years, we designed and constructed several new nano-drug delivery systems that significantly improve the efficacy of anti-tumor chemotherapeutic drugs and reduce their side effects, and their mechanisms of action are preliminarily revealed. 247 papers have been published in SCI journals (29 papers with IF>10), including the prestigious ones such as Adv Mater, Adv Drug Deliv Rev, Angew Chem Int Ed, ACS Nano, JACS and Adv Funct Mater, etc.; The papers are cited 5026 times accumulatively, and the maximum cited times of single article is 168; 18 invention patents are applied (10 granted); 1 Market and 2 IDA are obtained, especially the first nano-formulation aiming at improving the therapeutic effects against multidrug resistance at home and abroad has been investigated and developed; Being invited to make special or conference reports in domestic and international academic conferences for more than 60 times; 2 first Shanghai Pharmaceutical Technology Award are obtained. The multidisciplinary and tightly integrated innovative researching group aiming at developing new theories, new technologies and new methods of anti-cancer drug delivery systems, improving the therapeutic efficacy of drugs and translating them to the clinical applications has formed, which plays a leading and exemplary role in the drug delivery system field at home and abroad.